Neuroblastoma-specific cytotoxicity mediated by the Mash1-promoter and E. coli purine nucleoside phosphorylase

Yvonne Arvidsson1, Venil Sumantran, Fujiko Watt

  • 1Department of Cell Biology, Institute of Anatomy and Cell Biology, Göteborg University, Gothenburg, Sweden. yvonne.arvidsson@llcr.med.gu.se

Pediatric Blood & Cancer
|September 25, 2004
PubMed
Abstract

Insights

Researchers developed a targeted therapy for neuroblastoma using the Mash1 promoter to control the E. coli purine nucleoside phosphorylase (PNP) suicide gene, achieving selective cancer cell death.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Neuroblastoma originates from neural crest cells and often expresses the HASH1 transcription factor.
  • The study targets neuroblastoma cells, which are derived from neural crest cells.

Purpose of the Study:

  • To selectively eliminate neuroblastoma cells using gene therapy.
  • To investigate the efficacy of the Mash1 promoter in directing the expression of a suicide gene in neuroblastoma cells.

Main Methods:

  • Cloned the E. coli purine nucleoside phosphorylase (PNP) gene under the Mash1 promoter.
  • Transfected neuroblastoma and non-neuroblastoma cell lines.
  • Administered the prodrug F-araA to assess cell-specific toxicity.
  • Analyzed different Mash1 promoter lengths for optimal activity.

Main Results:

  • The Mash1 promoter showed significantly higher activity in neuroblastoma cells (17-58%) compared to non-neuroblastoma cells (1-6%).
  • Combining the shortest Mash1 promoter with the PNP gene resulted in 65% cytotoxicity in neuroblastoma cells.
  • Minimal cell death was observed in non-neuroblastoma cell lines.

Conclusions:

  • The Mash1 promoter confers selective toxicity in neuroblastoma cell lines.
  • This approach is feasible for gene-directed enzyme prodrug therapy (GDEPT) of neuroblastoma.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...